IDiyas

For the Inventor, By the Inventor

Gentofte, Denmark

Thomas Buch-Rasmussen

USPTO Granted Patents = 15

Average Co-Inventor Count = 4.1

ph-index = 14

Forward Citations = 842(Granted Patents)


Company Filing History:

goldMedal15 out of 1,777 
 
Novo Nordisk A/s
 patents

Years Active: 1999-2013

Loading Chart...
15 patents (USPTO):Explore Patents
1. 8518430 - Dry mouldable drug formulation (2013-08-27),
2. 8454997 - Solid dose micro implant (2013-06-04),
3. 8084053 - Dry mouldable drug formulation (2011-12-27),
4. 7666844 - Dry mouldable drug formulation (2010-02-23),
5. 7344766 - Injection-moulded stopper for medical containers (2008-03-18),
6. 6755810 - Medicament transferring device (2004-06-29),
7. 6680091 - Medicament container of polymer of cyclic hydrocarbon for storing a liquid medicament (2004-01-20),
8. 6660197 - Method for producing an elongated drug formation (2003-12-09),
9. 6562011 - Medication delivery device (2003-05-13),
10. 6485453 - Cassette for storing and insertion of solid medicine (2002-11-26),
11. 6482509 - Coating system providing low friction (2002-11-19),
12. 6461334 - Medical article with coated surfaces exhibiting low friction and protein adsorption (2002-10-08),
13. 6312413 - Cylinder ampoule (2001-11-06),
14. 6010485 - Working cylinder (2000-01-04),
15. 5945187 - Medicament container of polymer of linear olefin for storing a liquid (1999-08-31),

Title: Innovations by Thomas Buch-Rasmussen: Pioneering Pharmaceutical Patents

Introduction

Thomas Buch-Rasmussen, an inventive mind based in Gentofte, Denmark, holds an impressive portfolio of 15 patents. His work primarily focuses on developing advanced pharmaceutical formulations that enhance drug delivery methods, ensuring better patient outcomes.

Latest Patents

Among his latest contributions to the field of pharmaceuticals are two significant patents. The first, titled "Dry mouldable drug formulation," describes solid pharmaceutical compositions for parenteral injection, which include a binder and at least one therapeutic agent. This innovation allows for direct injection without the need for cannulas, streamlining the administration process for healthcare providers.

The second patent is centered around a "Solid dose micro implant," which features a solid pharmaceutical composition intended for parenteral administration. This composition includes an inner matrix housing at least one therapeutic agent, covered by a biodegradable and water-impermeable coating. This design enables the inner matrix to disintegrate upon contact with animal tissues or fluids, allowing for controlled drug release by carefully designing the exposed surface area.

Career Highlights

Thomas Buch-Rasmussen is a key contributor at Novo Nordisk A/S, a global leader in diabetes care and other chronic conditions. His innovative spirit and dedication to improving pharmaceutical formulations have cemented his reputation as a noteworthy inventor in the industry.

Collaborations

Throughout his career, Buch-Rasmussen has collaborated with esteemed colleagues, including James M. Flink and Philip E. Hansen. These partnerships highlight the collaborative nature of innovation within the pharmaceutical sector, encouraging the exchange of ideas and expertise among leading professionals.

Conclusion

Thomas Buch-Rasmussen's contributions to pharmaceutical innovation are notable, reflecting his commitment to advancing medical technology. With an impressive portfolio of patents, he continues to pave the way for new methodologies in drug administration, significantly impacting patient care and treatment efficacy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…